Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

IntReALL HR 2010: International study for treatment of childhood Relapsed high risk ALL (HR-ALL) 2010: A randomized Phase II Study

Leukaemia: Acute Lymphoblastic Leukaemia (high risk)

This study will assess the effectiveness of adding the drug bortezomib to the standard drug treatment for high risk (HR) acute lymphoblastic leukaemia (ALL) in children and adolescents who have relapsed. During the first month of relapse treatment, the child or adolescent will be randomly allocated to receive standard treatment with or without bortezomib.  This will demonstrate if inclusion of bortezomib will improve the chance of a complete response if provided in first month of relapse treatment.

Disease Stage: Relapse

Patient Age Range: <18 years

Sample Size: 100-250

Trial Sponsors:

  • International: Charite University Medicine Berlin
  • National: ANZCHOG

Read more at Clinical Trial Registry

ANZCHOG acknowledges the valuable support of IntReALL-HR by The Kids Cancer Project.